The Centers for Medicare and Medicaid Services finalized a rule this week eliminating the pathways that let medical devices designated as "breakthroughs" by the Food and Drug Administration qualify for extra payments without proving they clinically outperform existing alternatives. Starting in fiscal 2028, breakthrough-designated devices will no longer be able to skip the standard evidence requirements to receive supplemental Medicare payments in either the inpatient or outpatient setting. Reported on its own, this reads as a straightforward tightening: Medicare making life harder for medical-device makers.
The move is more interesting than that, and understanding it requires holding onto a distinction that is constantly blurred in health-policy coverage: the difference between coverage and payment. Coverage is whether Medicare will pay for a device at all. Payment, in the sense at issue here, is whether hospitals get extra money on top of their standard bundled reimbursement to account for a device being especially costly and novel. This rule tightens the second. And a separate, recent move by the same agency loosens the first. Once you separate the two, what looks like a simple cut turns into a deliberate rebalancing, and the logic behind it comes into focus.
Coverage and payment are two different levers
Medicare reimburses hospitals for most inpatient care through bundled payments tied to a diagnosis, a single sum meant to cover the whole episode regardless of the specific tools used. That system creates a problem for genuinely new, expensive devices: if a novel device costs far more than the bundle assumes, the hospital loses money using it, and may simply decline to adopt it, leaving patients without access even to something valuable. To address this, since 2001 Medicare has offered add-on payments for devices that are new, costly, and a clinical improvement over what exists. That add-on is the payment lever, and it is separate from the question of whether the device is covered in the first place.
The rule finalized this week concerns that payment lever, specifically an alternative route created in 2020 that let any FDA breakthrough-designated device qualify for the add-on without separately proving newness and clinical improvement. Meanwhile, on the coverage lever, CMS and the FDA announced in April a new mechanism called the RAPID pathway, designed to dramatically shorten the lag between FDA authorization and Medicare coverage for breakthrough devices, while pausing an earlier, little-used coverage program. So the agency is pulling the two levers in opposite directions at once: making coverage faster and easier to obtain, while making the extra payment harder to obtain without evidence. Read together, rather than in isolation, that is not a contradiction. It is a strategy.
What "breakthrough" actually certifies
The heart of the payment change is a question about what the breakthrough designation really means, and here a common misunderstanding does a lot of damage. The FDA's breakthrough device designation is a regulatory status that expedites review. It is granted relatively early, on the basis of preliminary evidence that a device may offer more effective treatment or diagnosis for a serious condition, in order to move it through the pipeline faster. It is, in essence, a statement of promise: this could be a significant improvement, so let us review it quickly. It is explicitly not a finding that the device does clinically outperform existing options, because that determination depends on fuller evidence that typically comes later.
The 2020 payment pathway blurred exactly that line. By letting a breakthrough designation substitute for a demonstration of clinical improvement, it treated a marker of potential as if it were proof of benefit. In the language that recurs across medicine, it allowed a surrogate to stand in for the substance it was only supposed to signal. A device could receive premium payment not because it had been shown to be better, but because it carried a label indicating it might be. The rule finalized this week re-couples the extra payment to the actual evidence: to get paid more, demonstrate that you are actually better, rather than pointing to a designation that says you could be.
The case for the change
There is a real argument that this re-coupling is correct, and it starts with what has happened to the designation itself. Breakthrough designations have become common, and because the bar is potential rather than proven superiority, paying a premium for anything carrying the label rewards potential over results. Some devices that look promising early do not pan out, and a payment system that pays top dollar on the strength of the label ends up overpaying for devices that turn out to be no better than what they replaced, precisely the cases where the surrogate failed to track the outcome it stood for.
The change also removes a distorted incentive. When a designation unlocks not just faster review but also extra money, the designation itself becomes something to chase, and the effort a company puts into securing the label can substitute for the effort of proving the underlying improvement the label was meant to indicate. A marker that becomes a payment target tends to stop reliably marking the thing it was created to mark. Requiring evidence of benefit before granting the premium restores the connection between paying more and getting more, which is a defensible principle for a program spending public money.
The real cost, stated fairly
None of that makes the change costless, and the objections to it are serious rather than merely self-interested. The alternative pathway existed to solve a genuine problem, sometimes called the valley of death, in which a device can be authorized by the FDA and even be genuinely good, yet fail to reach patients because hospitals cannot afford to use it under bundled payments and no add-on is available. Requiring full proof of clinical superiority before the extra payment can reintroduce that gap for exactly the devices the system should want to encourage.
Worse, there is a chicken-and-egg dimension that the evidence requirement does not fully resolve. The definitive evidence that a device clinically outperforms alternatives often cannot be generated until the device is in reasonably wide clinical use, but wide use may depend on the very payment that now requires the evidence. A genuinely superior device could be caught in that loop, unable to prove itself because it cannot get paid, and unable to get paid because it has not yet proved itself. This is why medical-device makers object, and why the concern is not only theirs: a bipartisan group of 82 lawmakers wrote earlier this year in support of comprehensive Medicare coverage of breakthrough technologies, reflecting genuine cross-party worry that payment and coverage lags keep good devices from patients. The access concern is legitimate, and a policy that tightens payment discipline does risk stranding some devices that deserve support.
Why the two moves fit together
This is where the coverage-versus-payment distinction stops being pedantic and becomes the key to the whole story. If CMS were only tightening payment, the access objection would land squarely. But the agency is simultaneously trying to make coverage faster through the RAPID pathway, which is aimed directly at the access problem from the other side. The implicit message of the combined moves is coherent: we will work to get your device covered faster, so it can reach patients, but we will not pay you a premium simply for holding a designation that signals potential, you must show real clinical benefit to earn the extra money.
Whether that rebalancing actually works is genuinely uncertain and rests on two open questions. The first is whether RAPID delivers the coverage acceleration it promises, and whether faster coverage adequately substitutes for the lost payment shortcut in getting good devices to patients, since coverage without adequate payment can still leave hospitals unable to afford adoption. The second is whether the evidence-for-payment bar is calibrated sensibly, demanding enough to stop premiums for unproven potential, but not so much that it traps genuinely superior devices in the chicken-and-egg loop. Neither question is answered yet, and the fate of the policy depends on both. The pieces are designed to fit together; whether they do in practice is the thing to watch.
How to read it
The accurate way to understand this week's rule is not as a simple cut to device payments but as a re-coupling of extra payment to demonstrated benefit, paired with a companion effort to speed coverage. The payment change fixes a real problem, a designation marking potential had been allowed to substitute for proof of benefit, letting devices earn premiums on the strength of a label rather than a result. The coverage change addresses the access problem that the payment discipline might otherwise worsen. Judged as a package rather than as a headline about eliminated pathways, it is an attempt to have both access and evidence discipline at once, rather than trading one for the other.
The genuine risk is the chicken-and-egg trap, in which requiring proof before payment strands devices that need adoption to generate the proof, and that risk is why the calibration of the evidence bar and the real-world speed of RAPID matter so much. The durable lesson is the distinction the coverage tends to collapse: coverage and payment are different levers, a designation and a demonstration are different things, and a policy that looks like a straightforward tightening can, seen whole, be a deliberate effort to pay for what works while still getting it to the people who need it. Whether Medicare has struck that balance correctly will be visible not in the rule's language but in whether good devices still reach patients under it.
Primary sources
- STAT for the report that CMS finalized the repeal of the alternative payment pathways allowing breakthrough-designated devices to qualify for supplemental inpatient and outpatient payments without proving substantial clinical improvement, effective fiscal year 2028, and for the earlier April coverage of the proposal, including the three standard add-on criteria (new, clinically improved, and especially costly) in place since 2001 and the 2020 alternative pathway that let breakthrough devices skip two of them.
- MedTech Dive for details of the RAPID coverage pathway announced jointly by CMS and FDA in April 2026, the estimate that about 40 devices would currently qualify with roughly 20 more potentially eligible, the pause of the Transitional Coverage for Emerging Technologies (TCET) pathway, and AdvaMed's prior criticism of TCET's limited scope.
- Foley Hoag and the CMS newsroom for the mechanics and timing of the RAPID pathway, the 60-day comment period, and the relationship among RAPID, TCET, and the standard national-coverage-determination process.
- Arnold & Porter for the history of Medicare breakthrough-device coverage efforts, the never-implemented MCIT program and the little-used TCET program, and the April 2026 letter from 82 bipartisan lawmakers supporting comprehensive Medicare coverage of breakthrough technologies.
- General health-policy background for the mechanics of diagnosis-related-group bundling, the New Technology Add-on Payment program, and the "valley of death" between FDA authorization and Medicare reimbursement.